The soft-tissue robotic-assisted surgery landscape is undergoing a structural realignment. For more than two decades,Intuitive Surgical maintained near-exclusive hegemony over general, urological, and gynecological robotic procedures through its da Vinci ecosystem. Over recent fiscal cycles, this market structure has been disrupted by fundamental shifts:key foundational patents have expired, hospital systems have faced mounting capital expenditure pressures, and surgical case